Lorne Albrecht

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg et al. · JAMA Dermatology · 2023 · 143 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis

Mark Lebwohl, Leon Kircik, Angela Moore et al. · JAMA · 2022 · 113 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Economic burden of moderate to severe plaque psoriasis in Canada

Adrian R. Levy, Alison Davie, Nicole C. Brazier et al. · International Journal of Dermatology · 2012 · 64 citations

Social Sciences, Dermatology, Economics +17

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Linda Stein Gold, Kim Papp, David M. Pariser et al. · Journal of the American Academy of Dermatology · 2021 · 55 citations

Medicine, Dermatology, Pharmacotherapy +7